73071
document
The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children . This double-blind and placebo-controlled clinical trial in autistic children had three objectives : ( a ) to replicate earlier findings that haloperidol administration is associated with a significant reduction of behavioral symptoms ; ( b ) to further assess its safety when given on a short-term basis ; and ( c ) to assess whether it has an effect on discrimination learning . Forty-five children , 2.02 to 7.58 years old ( M = 4.49 ) , completed this crossover design , with random assignment to treatment sequences . Haloperidol was shown to be a powerful therapeutic agent when administered for 4 weeks and free of side effects ; at doses ranging from 0.25 to 4.0 mg/day ( M = 0.844 ) , there was a clinically and statistically significant reduction of a variety of symptoms . Under the given conditions , the children failed to learn on either haloperidol or placebo .
73072
Intervention_Pharmacological
haloperidol
73073
Intervention_Control
placebo-controlled
73074
Intervention_Pharmacological
haloperidol
73075
Intervention_Pharmacological
Haloperidol
73076
Intervention_Pharmacological
haloperidol
73077
Intervention_Control
placebo
73078
Outcome_Mental
discrimination learning and behavioral symptoms
73079
Outcome_Mental
behavioral symptoms
73080
Outcome_Other
safety
73081
Outcome_Mental
effect on discrimination learning
73082
Outcome_Adverse-effects
side effects
73083
Outcome_Mental
variety of symptoms
73084
Participant_Condition
autistic
73085
Participant_Age
children
73086
Participant_Condition
.
73087
Participant_Sample-size
Forty-five
73088
Participant_Age
children
73089
Participant_Sample-size
2.02 to 7.58
73090
Participant_Sample-size
M = 4.49